Drug Trial Radar · NCT06542250
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
174
Planned (sponsor's estimate)
Start
Sep 18, 2024
Primary completion
Dec 18, 2029
Study completion Dec 18, 2029
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Aug 7, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase I/II study designed to evaluate if experimental T cell engaging antibody targeting CD20 AZD5492 is safe, tolerable and efficacious in participants with Relapsed or Refractory B-Cell Malignancies.
Conditions
- B-cell Malignancies
Interventions
AZD5492Drug
CD8/TCR based T-cell engaging antibody targeting CD20, which is administered subcutaneously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency of dose limiting toxicities (DLTs).Time frame: Module 1 - From the first administration of AZD5492 until the end of cycle 1 (up to 5 weeks).
- Safety evaluation of AZD5492: Number of participants with treatment-related adverse events.Time frame: Module 1 - From the first administration of AZD5492 within the duration of the treatment period, up to and including 90 (+7) days after the last dose of study treatment , but prior to subsequent cancer therapy.
- Tolerability evaluation of AZD5492: Number of participants with treatment-related adverse events.Time frame: Module 1 - From the first administration of AZD5492 within the duration of the treatment period, up to and including 90 (+7) days after the last dose of study treatment , but prior to subsequent cancer therapy.
Locations
31 sites in 10 countries. Site status is shown where the registry gives one.
Research Site
La Jolla, California · Recruiting
Research Site
Boston, Massachusetts · Withdrawn
Research Site
Rochester, Minnesota · Recruiting
Research Site
Hackensack, New Jersey · Recruiting
Research Site
New York, New York · Recruiting
Research Site
New York, New York · Recruiting
Research Site
Charlotte, North Carolina · Recruiting
Research Site
Winston-Salem, North Carolina · Recruiting
Research Site
Houston, Texas · Recruiting
Research Site
Seattle, Washington · Recruiting
Research Site
Melbourne, Australia · Recruiting
Research Site
Nedlands, Australia · Recruiting
Research Site
Calgary, Alberta, Canada · Recruiting
Research Site
Toronto, Ontario, Canada · Recruiting
Research Site
Montreal, Quebec, Canada · Recruiting
Research Site
Hangzhou, China · Recruiting
Research Site
Shanghai, China · Recruiting
Research Site
København Ø, Denmark · Recruiting
Research Site
Pessac, France · Recruiting
Research Site
Villejuif, France · Recruiting
Research Site
Göttingen, Germany · Recruiting
Research Site
München, Germany · Recruiting
Research Site
Ulm, Germany · Recruiting
Research Site
Würzburg, Germany · Recruiting
Research Site
Bologna, Italy · Recruiting
Research Site
Milan, Italy · Recruiting
Research Site
Chūōku, Japan · Recruiting
Research Site
Kashiwa, Japan · Recruiting
Research Site
Barcelona, Spain · Recruiting
Research Site
L'Hospitalet de Llobregat, Spain · Recruiting
Research Site
Madrid, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.